12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects

Phase 3 Withdrawn Viatris Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess efficacy and safety of pregabalin in treating moderate to severe Restless Legs Syndrome in comparison to placebo.

Timeline

Start: 2010-05
Primary completion: 2011-08
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pregabalin	Small molecule	150 mg	Oral
Subject	Pregabalin	Small molecule	300 mg	Oral

12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects

Summary

Timeline

Drugs

Indications